title: Bevacizumab--news from the fast lane?
authors.forename: Michael
authors.initials: M
authors.lastname: Weller
authors.forename: W K Alfred
authors.initials: WK
authors.lastname: Yung
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy*; D005910:Glioma / Q000188:drug therapy*; D006801:Humans
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068258:Bevacizumab
references.citation: Clin Cancer Res. 2007 Feb 15;13(4):1253-9
references.pmid: 17317837
references.citation: J Clin Oncol. 2008 Feb 20;26(6):1012-3; author reply 1013
references.pmid: 18281677
references.citation: Neurology. 2008 Mar 4;70(10):779-87
references.pmid: 18316689
references.citation: Neuro Oncol. 2008 Oct;10(5):700-8
references.pmid: 18697955